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safety and efficacy both for the device itself as well as BAT use. Decreases in SBP and DBP were seen at an
acute response as well as maintained during follow-up visits.
Conclusion: Baroreflex activation therapy is a new and exciting technology for potential treatment of
resistant hypertension. However, there is still a great deal of research and evaluation that must take place
before the Rheos system can be used as routine therapy. It should be used in patients who have exhausted
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Abstract   
 
Background:  Resistant hypertension is of growing concern due not only to its 
increasing prevalence, but also to the associated co-morbidities and their long-term 
consequences. This systematic review was performed to evaluate the efficacy of the 
Rheos System, a baroreflex activation device for use in patients diagnosed with resistant 
hypertension. 
 
Method:  Exhaustive search of available medical literature was conducted using 
Medline, CINAHL, Web of Science and Google Scholar. Exclusion criteria was applied 
and resulted in a total of three studies. Search terms used: baroreflex activation therapy, 
resistant hypertension, Rheos, carotid sinus, baroreceptor 
 
Results:  Three studies were evaluated on the Rheos system, two prospective cohort and 
one randomized control trial within the United States and Europe. Patients were 
prognostically similar between studies, based on age and number of hypertensive 
medications. Surgical implantation at the carotid sinus was evaluated for safety and 
efficacy both for the device itself as well as BAT use. Decreases in SBP and DBP were 
seen at an acute response as well as maintained during follow-up visits.  
 
Conclusion: Baroreflex activation therapy is a new and exciting technology for potential 
treatment of resistant hypertension. However, there is still a great deal of research and 
evaluation that must take place before the Rheos system can be used as routine therapy. It 
should be used in patients who have exhausted pharmaceutical agents as well as thorough 
lifestyle modifications to manage their hypertension. 
 
Keywords:  baroreflex activation therapy, resistant hypertension, Rheos, carotid sinus, 
baroreceptor 
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The Rheos System, A Baroreflex Activation Device for use in a Resistant 
Hypertension Population: A Systematic Review 
 
 
BACKGROUND 
 Hypertension continues to be a vogue topic amongst the medical community, both 
for its increasing prevalence as well as for its long-term complications. Current statistics 
show that hypertension is the second most common reason for medical office visits in the 
United States.1 It also remains the most frequent indication for prescription medications 
in adult patients.1 According to the seventh report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) 
guidelines, hypertension is defined as having a systolic blood pressure (SBP) of greater 
than 140 mmHg and/or a diastolic blood pressure (DBP) of greater than 90 mmHg.2  
 While many patients can successfully be managed by means of pharmaceutical 
intervention and/or lifestyle modifications, there is a population that continues to battle 
high blood pressure regardless of the aforementioned therapies. A recent US government 
study suggests that as many as 30% of hypertensive patients are not fully controlled with 
medications and are therefore deemed resistant to treatment.3 These patients are classified 
as resistant hypertension, or failure to attain an ideal blood pressure of <140/90 (or 
<130/80 for diabetic patients or those with chronic kidney disease).4 The definition also 
requires that the patient is compliant with at least three hypertension drugs, including a 
diuretic.4 This population of patients is frequently linked to co-morbid conditions such as 
diabetes, obesity and chronic kidney disease. Without adequate control of blood pressure, 
 7 
the compounding nature of these other associated conditions may dramatically reduce a 
patient’s quality of life.  
 This group of uncontrolled hypertensive patients is expected to grow in the 
coming years, as both life expectancy and the cardiovascular burden of obesity/metabolic 
syndrome increase dramatically. A new technology is making its way into the world of 
hypertension management by tapping into the central nervous system’s ability to assist in 
lowering blood pressure. By increasing the afferent signaling from baroreceptors to the 
brain, stimulation of the carotid sinus nerve will result in a decreased sympathetic 
response.5 This in turn will systemically lower blood pressure. Though this method was 
studied in the 1960s, technology was limited both in surgical technique and device 
precision. The implant was large in size and lacked the ability to adequately control 
electrical currents.6 Continuous research and development has led to the invention of a 
new device known as the Rheos Baroreflex Hypertension Therapy System. This system, 
which consists of a pulse generator, two leads and a programmer, operates via an external 
pulse generator.4-6 These electrical pulses stimulate the implanted carotid sinus device, 
with a goal of creating the desired effect of lowering a subject’s blood pressure. 
 This systematic review will evaluate and discuss the findings of current research 
on the Rheos System and determine its effectiveness for future implications in clinical 
practice. 
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METHOD 
 An extensive literature search was performed using Medline, CINAHL, Web of 
Science and Google Scholar. Keywords used in the literature search included “baroreflex 
activation therapy”, “resistant hypertension”, “Rheos”, “carotid sinus” and 
“baroreceptor”. These terms were utilized in database searches both individually and in 
combination with one another. Inclusion criteria required studies performed on humans 
only as well as articles that discussed the Rheos system specifically.  
 
RESULTS 
 Three studies returned and all were included due to the limited nature of the topic. 
These studies included two prospective cohort and one randomized controlled trial. All 
were completed within the United States or Europe and were performed in the past seven 
years. The GRADE System was applied to each article (see Table I: Characteristics of 
Studies) to evaluate for the strength of evidence given for the clinical question at hand.  
Study #1: European study 
 This article5 was a prospective cohort study that took place in nine clinical centers 
throughout Europe. A total of forty-five nonrandomized subjects were deemed 
appropriate for surgery based off of the established exclusion criteria. This criteria 
included prior baroreflex failure, significant orthostatic hypotension, cardiac arrhythmias, 
chronic atrial fibrillation, clinically significant cardiac valvular disease or hypertension 
secondary to a treatable cause, carotid artery atherosclerosis with >50% stenosis as 
determined by ultrasonography, prior implant or radiation in the carotid sinus region, 
currently implanted electrical medical devices, dialysis and pregnancy or contemplating 
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pregnancy. The mean age of subjects was 54 (standard deviation +/-9). These forty-five 
subjects were implanted with the Rheos device between March 2004 and November 
2007. Due to safety and efficacy protocols that were not discussed in the article, three 
subjects were excluded from analysis following implantation.  There were also four 
subjects that dropped out of the trial and one additional subject that missed the required 
visits, leaving thirty-seven subjects that were evaluable.5 
 The device was activated in all patients after one month of implantation to allow 
time for surgical wound healing. Subjects were analyzed on a monthly basis for the first 
three months following device activation, then on a yearly basis. At these visits, blood 
pressure measurements were taken both sitting and after ambulation to determine efficacy 
of the Rheos device. In addition to these measurements, the study evaluated functional 
safety measures by testing the subject’s activity while exercising in a 6-minute hall walk 
test, combined with changes in orthostatic blood pressure at 1, 3 and 5-minute intervals of 
upright standing. This occurred after the subject had been in the supine position for 5 
minutes. All subjects were maintained on their previously prescribed anti-hypertensive 
medications, which ranged from a total of 3 to 9 prescriptions per subject. The 6-minute 
hall walk was used in 14 subjects, they improved by an average of 48 meters at the 1 year 
evaluation. Much like the hall walk test, orthostatic blood pressure was a measurement 
only performed in a percentage of the subjects. Regardless, there was no evidence of 
orthostatic hypotension, nor concerns with either syncope or collapse in the 32 subjects 
evaluated with this test. The article briefly mentions a significant increase in serum 
creatinine in 22 of the 26 participants at the 1-year evaluation, but fails to provide either 
data or an explanation for this finding.5  
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 This study aimed to measure both procedure safety as well as device safety by 
monitoring serious adverse events (SAE). These included the following events: death, 
life-threatening situation, inpatient hospitalization, prolongation of existing 
hospitalization, or persistent or significant disability. There was a total of 8 SAEs in the 
cohort of 42 subjects, 7 as a result of the surgical procedure and 1 in relation to the device 
itself. Of these SAEs, 1 was fatal and 2 were corrected by means of additional surgery.5 
 Efficacy of the Rheos device was provided by mean change in blood pressure at 
each office evaluation. At the 3-month visit, SBP decreased by an average of 21 mmHg 
(SD +/- 4), 30 mmHg (SD +/- 6) at the 1-year visit and 33 mmHg (SD +/- 8) for subjects 
who continued in the study through the 2 year evaluation. An e-mail to the study 
correspondent was sent as a request for individual data on subject’s blood pressure 
readings, but failed to receive a response.5 
Study #2: phase II Rheos feasibility trial 
 This study6 was a phase II feasibility study with a prospective cohort format. It 
was performed in the United States and managed by the Food and Drug Administration. 
Ten non-randomized subjects were approved for device implantation, ranging in ages 
from 33 to 71.  There were four females and six males, all having an established 
diagnosis of resistant hypertension per JNC-7 definition. The entrance criteria for this 
study included exhaustion of anti-hypertension treatment, removal of any secondary 
causes of hypertension, lack of baroreflex dysfunction and lack of carotid artery disease.6  
 Since this article discussed the initial evaluation of the Rheos device within 
American borders, it discussed at length both the surgical details of carotid lead 
placement as well as anesthetic induction and procedure completion. It was the only 
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study to discuss and evaluate the effects of the device’s capability for voltage 
administration between 1 and 7.5 V. This dose-response testing was performed both in 
the surgical suite prior to wound closure for acute response analysis and once again prior 
to hospital discharge (either day 1 or 2 post-operatively). During these testing intervals, 
voltage was initiated at 1 V and then increased by 1-V intervals every 60 seconds until 
the selected maximum dose of 6 V was reached. The exception to reaching 6 V was if the 
subject reached one of three hemodynamic end points, including a mean arterial blood 
pressure of <60 mmHg, a heart rate of <50 per minute or a SBP of <90 mmHg. In these 
cases, the maximum tolerated voltage was recorded. Results from the intra-operative 
voltage testing resulted in a mean SBP decrease of 37 mmHg at 6 V. The DBP also 
decreased significantly by a mean of 24 mmHg and the heart rate decreased on average 
from 71 to 63 beats per minute.6  
 During the first post-operative dose testing, the mean SBP dropped by 41 mmHg, 
with DBP and heart rate displaying a significant mean drop of 19 mmHg and 9 beats per 
minute, respectively. In these post-operative readings, it is noted that only 5 of the 10 
patients were able to reach a 6 V dose, as hemodynamic end points were reached at either 
4 or 5 V for these patients.6  
 In this study, there were no unanticipated serious adverse events (SAEs) from 
either the procedure or the device. The article does not disclose their interpretation of an 
unanticipated event, but also notes that there were no perioperative deaths as a result of 
the Rheos device placement. The only unwanted post-surgical effect noted by an 
undisclosed number of subjects was muscle twitching, which was most likely a result of 
peripheral nerve stimulation from the implant itself.6   
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 The mean follow-up as of publication of the article (May 2006) was 10 months. 
All patients had completed a minimum of 4 months follow-up. During this follow-up 
time frame, 2 of the subjects required device battery replacements and 1 subject suffered 
a non-fatal infection. This infection occurred after 4 months of follow-up and resulted in 
excision of the device. As of publication, the article states that the subject was not re-
implanted.6 
Study #3: phase III Rheos feasibility trial 
 This study4 was a phase III feasibility study and is the only randomized control 
study to date on this topic. Both subjects and investigators were blinded to the treatment 
groups until each participant’s 12-month clinical visit. This study was performed in the 
United States and approved by the FDA. Forty-nine clinical centers evaluated potential 
subjects between March 2007 and November 2009. A total of 326 subjects were eligible 
for implantation, with each of the forty-nine centers given up to two non-randomized 
subjects to initially place the device. This was seen as a means of establishing the 
learning curve of the new Rheos procedure and a total of 55 subjects were categorized 
under this stage of the study, with all but 4 displaying an acute response. If an immediate 
baroreflex activation therapy (BAT) response was not detected before surgical closure, 
the device was deemed ineffective in that patient and explanted. Two of the non-
randomized subjects had the device explanted following surgery due to infection, leaving 
a total of 265 subjects for randomization. A 2:1 ratio between the study groups was 
created, placing 181 individuals in Group A (immediate BAT) and 84 into Group B 
(delayed BAT until after month 6).4  
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 The study aimed to determine both the safety and efficacy of the Rheos system by 
implementing five coprimary endpoints. These included analysis of both acute and 
sustained efficacy, as well as procedural safety, BAT safety and device safety. Of these 
endpoints, neither the acute efficacy nor the procedural safety criteria was met. The acute 
efficacy endpoint was established to determine whether immediate BAT following 
implantation indicated an advantage over a delayed response to 6 months post-
operatively. This was analyzed by measuring the number of subjects in each group that 
attained a drop in SBP by at least 10 mmHg between Month 0 and Month 6. Results 
indicated that 54% of subjects in Group A met this criteria and 46% of subjects in Group 
B. Due to the 20% superiority margin that was put in place for this endpoint, the goal was 
not reached. The second endpoint that was not met related to procedural safety. This was 
intended to analyze the event-free rate of subjects who had neither a procedure nor 
system-related SAE within 30 days of implantation. The investigators established an 82% 
objective performance criterion based off of prior literature on event rates for other 
implantable devices such as defibrillators and pacemakers. This endpoint reached a 
74.8% event-free rate, with a large portion of subjects (9.2%) suffering the result of 
improper carotid sinus lead placement, leading to temporary or permanent nerve damage. 
Other indications for failure included 4.8% of subjects with a generalized surgery 
complication and 2.6% with wound complications or respiratory concerns. The article 
does not disclose the reasons behind the final 2% of events, but does indicated that 76% 
of all previously-mentioned occurrences resolved completely.4 
 The three endpoints that were successfully reached in this study included 
sustained efficacy, BAT safety and device safety. The sustained efficacy was determined 
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by comparing the response of Group A subjects between their Month 6 and Month 12 
SBP readings. If the decrease in SBP at Month 12 from baseline was at least half the 
decrease measured between baseline and Month 6, then the criteria for a sustained 
response was met. An example of this finding would be to have a Month 12 reading of at 
least 15 mmHg lower than baseline, if the Month 6 reading was 30 mmHg lower than 
baseline. Other results included the objective performance criterion, which was 65% and 
was surpassed with 88% of subjects fulfilling this criterion. BAT safety was met by 
comparing Group A and Group B post-operatively between the 30-day mark and the 
Month 6 visit. Any therapy-related SAEs were noted as a concern for BAT safety and 
included hypotension, bradycardia and other events related to treating hypertension. A 
non-inferiority margin was established at 15%, suggesting that less than a 15% difference 
between groups would be grounds for BAT safety. Results indicated that there was a 
2.4% increase of event-free subjects in Group A versus Group B. The most significant 
even that occurred in both groups was for hypertensive emergency. However, the number 
of these events was reduced by 40% in Group A due to immediate activation of BAT, 
signifying a relative risk reduction of 40% by not delaying activation of the Rheos 
device. Finally, the endpoint of device safety was successfully attained by requiring a 
Rheos device event-free rate of 72%. To reach this endpoint, investigators analyzed all 
SAEs and hypertension-related events between the 30-day post-operative mark and the 
Month 12 visit. This percentage was established based off of similar implants such as 
defibrillators and pacemakers. The study indicated an event-free rate of 87.2%.4 
 The study did not provide data on individual values of successful SBP decreases 
below 140 mmHg, but did provide a graph to display the proportion of subjects in each 
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group that achieved this level. An estimate from the article’s figure suggests that 42% of 
Group A achieved a SBP of less than or equal to 140 mmHg at the 6 month evaluation, 
while only 22% of Group B achieved this level. The difference between the two groups 
become almost insignificant at the Month 12 evaluation though, as roughly 52% of Group 
A and 51% of Group B attain a SBP of less than or equal to 140 mmHg. This results in a 
NNT (number needed to treat) of 6 based off of the Month 6 evaluation.4 
 In total, results of the study show that 63% of all subjects reached a SBP of less 
than or equal to 140 mmHg, with 81% of subjects dropping a minimum of 10 mmHg 
since implantation. However, it is noted that a significant number of subjects in Group B 
achieved a SBP of <140 mmHg before BAT was activated. While this positive finding is 
well-received, there are concerns with the fact that subjects and their clinicians had 
permission to alter hypertension medications as needed, leading to questions of pre-study 
medication compliance as well as necessary standardization in future studies.4 
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DISCUSSION 
 Evaluation of these three trials suggests that the groundwork has been laid 
accordingly for the current level of device knowledge (see Table II). It is evident that the 
Rheos device works well in the resistant hypertension population, but comes with the 
assumed risks of surgical procedures such as infection, anesthesia use and improper 
device placement. As a whole, the studies addressed multiple variables involved in the 
Rheos system, including voltage-response testing, blinded randomization, acute and 
sustained response, as well as safety of barereflex activation therapy (BAT), surgery and 
the device itself. 
 It is important to note that the phase II feasibility study performed in the United 
States presented with publication bias. Though the trial was monitored by the FDA, five 
of the doctors associated with the study receive clinical trial reimbursement to cover the 
study’s expenses. Also, 4 of the doctors are either paid consultants of the Rheos 
manufacturer or employees of the company itself.  
 Currently, the ideal management of resistant hypertensive patients is through 
alterations in lifestyle combined with pharmaceutical intervention. These methods are 
established in the literature and in clinical practice, deeming them safer than any new 
surgical device.  
Limitations of Study 
 Although these studies overall were well done, they are limited simply by the 
quantity of data and by the fact that only one randomized control trial (RCT) has been 
performed. Future research with additional RCT studies is necessary, as well 
implementing a required level of proficiency for surgeons involved in the placement of 
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the Rheos device. The technique of device placement at the carotid sinus is still in its 
infancy; until the medical community has established an efficient and standardized 
approach to surgical implantation of Rheos, this device will most likely remain in clinical 
trials alone.  
 
CONCLUSION 
 Baroreflex activation therapy is a new and exciting technology for potential 
treatment of resistant hypertension. Though three in-human studies have been completed 
to date, there is still a great deal of research and evaluation that must take place before the 
Rheos system can be used as routine therapy. The device requires continued evaluation 
for both procedural safety as well as long-term efficacy.  
 Should BAT become a standard treatment for resistant hypertension, it would be 
limited to those patients who have pursued all other means of blood pressure 
management, both by exhausting all potential pharmaceutical agents as well as thorough 
lifestyle modifications. While the device may have a strong future in treating those 
patients who have failed at other therapy modalities, there remains an additional surgical 
risk that undeniably must be considered before pursuing such an option.  
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Figure I: Reproduced with permission from CVRx, manufacturer of the Rheos System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
